1.570USD+9.03%Mkt Cap: 64.56M USDP/E: —Last update: 2026-05-22
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: t…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap64.56M USD
Enterprise Value55.73M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-1.01M USD
Revenue/Share—
Last Price1.570 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees44
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.06
PEG—
EV/EBITDA-6.53
EV/Revenue—
P/S—
P/B-1.72
EPS (TTM)-0.21
EPS (Forward)-0.47
52W Range
1.17517% of range3.440
52W High3.440 USD
52W Low1.175 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE3.13%
ROA-3.88%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.77M USD
CapEx (TTM)50.00K USD
FCF Margin—
FCF Yield19.38%
Net Debt-7.62M USD
Net Debt/EBITDA0.89
Balance Sheet
Debt/Equity-0.01
Current Ratio1.09
Quick Ratio0.64
Book Value/Sh-0.8390 USD
Cash/Share0.1910 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.41.12M
Float31.69M
Insiders14.89%
Institutions14.55%
Short Interest
Short Ratio224.7d
Short % Float6.42%
Short % Out.5.32%
Shares Short2.19M
Short (prev mo.)2.20M
Technical
SMA 501.603 (-2.1%)
SMA 2001.730 (-9.2%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)14.35K
Avg Vol (10d)20.30K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—